Objective To investigate the current situation of the use of endoscopic therapies for esophagogastric variceal bleeding(EGVB)in portal hypertension in Southern China area.Methods We carried out an online questionnaire survey to investigate the use of endoscopic therapies for EGVB in Guangdong province,Guangxi Zhuang Autonomous Region and Hainan province in South China.Questions included endoscopic choices for preventing EGVB,management of acute EGVB,management of gastric varices and special types of varices,fundamental treatment of cirrhosis-derived portal hypertension,and the follow up of endoscopic therapies.Hospital treatment options were expressed as percentage.Comparisons of guideline adherence among hospitals of different regions were performed with Chi-square or Fisher's exact test when appropriate.Results A total of 81 hospitals participated the study.The survey showed that the leading indication of endoscopic therapies was treating acute EGVB(60.5％).For primary and secondary prophylaxis of EGVB,adherence to national guideline was 55.6％,and no significant differences of the adherence were observed among different provinces(P=0.976 and 0.186,respectively).As much as 92.6％hospitals preferred endoscopic therapies treating acute EGVB,and most of the hospitals carried out emergency endoscopies within 12-24 hours after the presentation of bleeding(82.7％).In the treatment of various types of gastric varices and ectopic varices,cyanoacrylate injection-based procedures(including cyanoacrylate injection combined with sclerotherapy and cyanoacrylate injection alone)were the most prevalent procedures.81.5％hospitals routinely used non-selective β-blockers for cirrhosis-derived portal hypertension,and main drugs were propranolol(80.2％)and carvedilol(19.8％).Conclusion This survey showcases that various endoscopic procedures for EGVB treatment have been conducted in Southern China.Participating hospitals are active to perform emergency endoscopies for acute EGVB,however,they are inadequate in following recommendations regarding primary and secondary prophylaxis of EGVB.It is necessary to improve guideline compliance for EGVB therapy in the future.
维普
万方数据
